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POLISH GUIDELINES FOR COSTING IN
PHARMACOECONOMIC EVALUATION IN
COMPARISON TO EXISTING GUIDANCE FOR
COSTING IN OTHER COUNTRIES
Orlewska E1, Mierzejewski P2, Cel M1
1National Institute of Public Health, Warsaw, Poland; 2Agency
for Registration of Medicinal Products, Medicinal Devices &
Biocides, Warsaw, Poland
OBJECTIVES: Standardisation of costs is an important
topic within the methodology of economic evaluation.
National guidelines, that formulate the formal require-
ments for studies to be considered when deciding on 
the reimbursement of new medical therapies, are rather
global with respect to costing. In an attempt to further
standardise the costing methods some countries have
issued additional guidelines for cost calculations. The aim
of this study is to compare project of Polish guidelines for
costing with existing international guidance, highlighting
areas of agreement and dissent. METHODS: Existing
guidelines for costing were reviewed, analysed and 
comparison between they and their Polish counterpart
was subsequently undertaken. RESULTS: Guidelines for
costing in pharmacoeconomic evaluations have been
issued in Australia, Canada and the Netherlands. The
Australian costing guide provides an extensive list with
standard costs of hospital services. The use of these stan-
dard costs is obligatory in the case of formal appraisal
studies for new medications. The Canadian guidance pre-
sents basic principles and methods only and does not yet
present a standard cost list. The Dutch manual strikes the
balance between guidance mentioned above and with the
introduction of standard values and the way the standard
costs are treated introduces some new elements to stan-
dardisation of costs in economic evaluations. In Polish
project basic principles, methods for measurement and
valuation and reporting of costs are described. The 
standard values and costs are presented and recom-
mended for studies that support submissions to acquire
reimbursement. Standard costs are calculated as weighted
mean, maximum and minimum values based on available
data from sick founds and are as patient- and disease-spe-
ciﬁc as possible. CONCLUSIONS: The guidelines for
costing ﬁt with current practice and the availability of
data in each country. They contribute to the comparabil-
ity and generalisability of economic evaluations and can
deliver beneﬁt for healthcare decision makers.
PHP17
SOURCES OF VARIATION IN DRUG COSTS
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Brown J, Menzin J, Friedman M
Boston Health Economics, Inc, Waltham, MA, USA
OBJECTIVE: Drug spending is the fastest growing 
component of state Medicaid budgets. This study assesses
the extent of state variation in Medicaid drug spending
among all 50 states in 2001. METHODS: Data on 
Medicaid drug cost, users, and number of prescriptions
were compiled for 2001 for all 50 states and evaluated
by class and product. Levels of drug use and spending
were compared across states and expressed on a per-user
basis. RESULTS: Medicaid drug expenditures totaled
almost $25 billion in 2001, more than double the outlay
in 1996; drugs now account for approximately 12% of
Medicaid spending. Nationwide, the top 5 drug classes
(antipsychotics, antidepressants, gastrointestinal agents,
anticonvulsants, and antivirals) accounted for 36% of
drug expenditures, and the top 5 drugs accounted for
16% of total expenditures. The average cost per user was
about $1200 across all states. This ranged from more
than $2000 for Connecticut ($2732), New Jersey
($2159), and Rhode Island ($2130) to less than $800 for
Delaware ($756), Texas ($743), Wyoming ($714), New
Hampshire ($683), and Maryland ($616). The number of
prescriptions dispensed rather than the average cost per
prescription largely drove the differences in cost per user.
The 10 states with the highest per-user cost averaged 33
prescriptions per user, compared to an overall average of
22, and an average of 15 for the bottom 10 states. The
average cost per prescription was $53 for the 10 states
with the highest per-user cost and $51 for the bottom 
10 states. CONCLUSIONS: The number of prescriptions
per user, and not the cost per prescription, drives a four-
fold variation among states in the average prescription
drug cost per beneﬁciary. Explanatory factors should be
explored, such as population density, state drug cost 
containment strategies, disease epidemiology, and state
health and social policies.
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THE ELDERLY DUE TO INAPPROPRIATE
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Fu AZ, Liu GG
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OBJECTIVE: Inappropriate prescribing can cause signif-
icant adverse events for all age groups. It perhaps would
be most costly when it happens to the elderly in particu-
lar. Most existing studies explored the high prevalence
and demographic variables as risk factors of inappropri-
ate prescribing. This study examines the healthcare cost
utilization outcomes of inappropriate drug use by the
elderly at the national level. METHOD: Inappropriate
medications were deﬁned by well-accepted Beers explicit
criteria. OLS and negative binomial models were
employed to estimate the functions with different depen-
dent variables using the 1996 Medical Expenditure Panel
Survey (MEPS), a national representative sample of the
non-institutionalized populations. In order to generalize
the result to the whole US nation, complex survey sample
design was adjusted in modeling. RESULTS: Compared
with elderly using proper medications, inappropriate pre-
